Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Alcon Research136 enrolled

Overview

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

136

Conditions

AMD

Interventions

anecortave acetateDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * AMD disease Exclusion Criteria: * Age

Locations (1)

Facility

Beachwood, Ohio, United States

Outcomes

Primary Outcomes

Mean change from the baseline in logMAR visual acuity score at Month 6

Secondary Outcomes

% patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.